Rothschild & CO Asset Management Us Inc. Revance Therapeutics, Inc. Put Options Transaction History
Rothschild & CO Asset Management Us Inc.
- $6.56 Billion
- Q4 2022
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
33Shares Held
10.6MCall Options Held
370KPut Options Held
0-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL423KShares$1.09 Million0.0% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL237KShares$610,1410.0% of portfolio
-
Credit Suisse Ag Zurich, V8180KShares$462,9800.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...